• Molecular NameRapacuronium
  • SynonymRapacuronium bromide
  • Weight597.905
  • Drugbank_IDN/A
  • ACS_NO156137-99-4
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)2.24
  • pkaN/A
  • LogD (pH=7, predicted)0.94
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-0.45
  • LogSw (predicted, AB/LogsW2.0)4.3
  • Sw (mg/ml) (predicted, ACD/Labs)24.2
  • No.of HBond Donors0
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds9
  • TPSA55.84
  • StatusN/A
  • AdministrationIntravenous
  • PharmacologyA rapidly acting, non-depolarizing neuromuscular blocker used in modern anaesthesia, to aid and enable endotracheal intubation, which is often necessary to assist in the controlled ventilation of unconscious patients during surgery and sometimes in intensive care. As a non-depolarizing agent, it does not cause initial stimulation of muscles before weakening them.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding69.0
  • Volume of distribution (VD)Total apparent, 221 (124 to 285) mL/kg (healthy individuals); 331 (284 to 488) mL/kg (patients with cirrhosis); steady state, 0.193 to 0.457 L/kg; lower in those with chronic renal failure compared to those with normal function and in men compared with women.
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHydrolyzed to active metabolites CYP system not involved
  • Half life90 min (range 72 to 184 min).
  • ExcretionRenal and fecal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A